Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
TransCode Therapeutics Inc (NASDAQ:RNAZ) shares are trading lower by 40.6% to $0.84 during Monday's session after the company disclosed plans for a potential reverse stock split in an open letter to its shareholders. The proposal arises from the company's failure to meet the Minimum Bid Requirement, as its common stock did not close at $1.00 or more for any ten-day period ending May 6.
TransCode Therapeutics Inc（納斯達克股票代碼：RNAZ）股價在週一的交易中下跌40.6％，至0.84美元，此前該公司在給股東的一封公開信中披露了可能的反向股票拆分計劃。該提案源於該公司未能滿足最低出價要求，因爲在截至5月6日的十天內，其普通股收盤價均未達到1.00美元或以上。
Nasdaq has consequently notified TransCode Therapeutics of potential delisting, prompting the company to seek shareholder approval for the reverse split. In the event of a reverse split, the Board of Directors would be authorized to take action if they believe it serves the best interests of both the company and its shareholders.
因此，納斯達克已通知TransCode Therapeutics可能退市，這促使該公司尋求股東批准反向拆分。如果發生反向分裂，如果董事會認爲這符合公司及其股東的最大利益，則將有權採取行動。
While there's no assurance that the reverse split alone will prevent delisting, the company and its advisors believe it represents the best chance to maintain its Nasdaq listing. TransCode Therapeutics underscored its commitment to exploring every avenue to safeguard shareholder interests and ensure continued listing on The Nasdaq Capital Market.
儘管無法保證僅憑反向拆分就能阻止退市，但該公司及其顧問認爲這是維持其在納斯達克上市的最佳機會。TransCode Therapeutics強調其致力於探索一切途徑來維護股東利益，並確保繼續在納斯達克資本市場上市。
Should I Sell My RNAZ Stock?
我應該賣出我的 RNAZ 股票嗎？
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
是賣出還是持有股票在很大程度上取決於投資者的策略和風險承受能力。波段交易者可能會出售表現跑贏大盤的股票以鎖定資本收益，而長期投資者可能會在股價進一步增長的預期下渡過難關。
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
同樣，願意最大限度地減少損失的交易者可能會賣出下跌一定百分比的股票，而長期投資者則可能將其視爲以折扣價購買更多股票的機會。
Shares of TransCode Therapeutics (NASDAQ:RNAZ) have lost 99.62% year to date. This compares to the average annual return of -92.39%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
迄今爲止，TransCode Therapeutics（納斯達克股票代碼：RNAZ）的股價已下跌99.62％。相比之下，平均年回報率爲-92.39％，這意味着該股的表現低於歷史平均水平。投資者可以將股票的走勢與其歷史表現進行比較，以評估這是正常走勢還是潛在的交易機會。
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. TransCode Therapeutics stock currently has an RSI of 86.23, indicating overbought conditions.
投資者也可以考慮市場動態。相對強弱指數可用於表明股票是超買還是超賣。TransCode Therapeutics股票目前的相對強弱指數爲86.23，這表明存在超買情況。
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
如需分析工具、圖表數據和獲取獨家股票新聞，請查看 Benzinga PRO。免費試用。
RNAZ has a 52-week high of $309.60 and a 52-week low of $0.42.
澳大利亞央行的52周高點爲309.60美元，52周低點爲0.42美元。